Genital warts treatment: Beyond imiquimod

References

• Stanley MA. Human papillomavirus vaccines. Curr Opin Mol Ther. 2002;4:15–22. PMID:11883690
   PubMed Web of Science ®Google Scholar
• Stanley MA. Genital human papillomavirus infections: current and prospective therapies. J Gen Virol. 2012;93:681–91. doi:10.1099/vir.0.039677-0. PMID:22323530.
   PubMed Web of Science ®Google Scholar
• Frazer IH. Development and implementation of papillomavirus prophylactic vaccines. J Immunol. 2014;192:4007–11. doi:10.4049/jimmunol.1490012. PMID:24748633.
   PubMed Web of Science ®Google Scholar
• Frazer IH, Leggatt GR, Mattarollo SR. Prevention and treatment of papillomavirus-related cancers through immunization. Annu Rev Immunol. 2011;29:111–38. doi:10.1146/annurev-immunol-031210-101308. PMID:21166538.
   PubMed Web of Science ®Google Scholar
• Jardine D, Lu J, Pang J, Palmer C, Tu Q, Chuah J, Frazer IH. A randomized trial of immunotherapy for persistent genital warts. Hum Vaccin Immunother. 2012;8:623–9. doi:10.4161/hv.19319. PMID:22634446.
   PubMed Web of Science ®Google Scholar
• Frazer IH. Interaction of human papillomaviruses with the host immune system: a well evolved relationship. Virology. 2009;384:410–4. doi:10.1016/j.virol.2008.10.004. PMID:18986661.
   PubMed Web of Science ®Google Scholar
• Frazer I. Correlating immunity with protection for HPV infection. Int J Infect Dis. 2007;11 Suppl 2:S10–16. doi:10.1016/S1201-9712(07)60016-2. PMID:18162240.
   PubMed Web of Science ®Google Scholar
• Samarakoon S. Genital warts. Ceylon Med J. 1999;44:159–61. PMID:10895265.
   PubMedGoogle Scholar
• Anonymous. Sexually transmitted disease quarterly report: anogenital warts and anogenital herpes simplex virus infection in England and Wales. Commun Dis Rep CDR Wkly. 2000;10:230–2. PMID:10927859.
   PubMedGoogle Scholar
• Patel H, Wagner M, Singhal P, Kothari S. Systematic review of the incidence and prevalence of genital warts. BMC Infect Dis. 2013;13:39. doi:10.1186/1471-2334-13-39. PMID:23347441.
   PubMed Web of Science ®Google Scholar
• Tayib S, Allan B, Williamson AL, Denny L. Human papillomavirus genotypes and clinical management of genital warts in women attending a colposcopy clinic in Cape Town, South Africa. S Afr Med J. 2015;105:679–84. doi:10.7196/SAMJnew.7890..
   PubMed Web of Science ®Google Scholar
• Hernandez BY, Shvetsov YB, Goodman MT, Wilkens LR, Thompson PJ, Zhu X, Tom J, Ning L. Genital and extra-genital warts increase the risk of asymptomatic genital human papillomavirus infection in men. Sex Transm Infect. 2011;87:391–5. doi:10.1136/sti.2010.048876. PMID:21602516.
   PubMed Web of Science ®Google Scholar
• Mayeaux EJ, Jr., Dunton C. Modern management of external genital warts. J Low Genit Tract Dis. 2008;12:185–92. doi:10.1097/LGT.0b013e31815dd4b4. PMID:18596459.
   PubMed Web of Science ®Google Scholar
• Ockenfels HM. Therapeutic management of cutaneous and genital warts. J Dtsch Dermatol Ges. 2016;14:892–9.
   Web of Science ®Google Scholar
• Lopaschuk CC. New approach to managing genital warts. Can Fam Physician. 2013;59:731–6. PMID:23851535
   PubMed Web of Science ®Google Scholar
• Kofoed K, Norrbom C, Forslund O, Moller C, Froding LP, Pedersen AE, Markauskas A, Blomberg M, Baumgartner-Nielsen J, Madsen JT, et al. Low prevalence of oral and nasal human papillomavirus in employees performing CO2-laser evaporation of genital warts or loop electrode excision procedure of cervical dysplasia. Acta Derm Venereol. 2015;95:173–6. doi:10.2340/00015555-1912. PMID:24941064.
   PubMed Web of Science ®Google Scholar
• Yew YW, Pan JY. Complete remission of recalcitrant genital warts with a combination approach of surgical debulking and oral isotretinoin in a patient with systemic lupus erythematosus. Dermatol Ther. 2014;27:79–82. doi:10.1111/dth.12059. PMID:24703263.
   PubMed Web of Science ®Google Scholar
• Chandra J, Miao Y, Romoff N, Frazer IH. Epithelium expressing the e7 oncoprotein of hpv16 attracts immune-modulatory dendritic cells to the skin and suppresses their antigen-processing capacity. PLoS One. 2016;11:e0152886. doi:10.1371/journal.pone.0152886. PMID:27031095.
   PubMed Web of Science ®Google Scholar
• Abd Warif NM, Stoitzner P, Leggatt GR, Mattarollo SR, Frazer IH, Hibma MH. Langerhans cell homeostasis and activation is altered in hyperplastic human papillomavirus type 16 E7 expressing epidermis. PLoS One. 2015;10:e0127155. doi:10.1371/journal.pone.0127155. PMID:25992642.
   PubMed Web of Science ®Google Scholar
• Barnard P, McMillan NA. The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-alpha. Virology. 1999;259:305–13. doi:10.1006/viro.1999.9771. PMID:10388655.
   PubMed Web of Science ®Google Scholar
• Barnard P, Payne E, McMillan NA. The human papillomavirus E7 protein is able to inhibit the antiviral and anti-growth functions of interferon-alpha. Virology. 2000;277:411–9. doi:10.1006/viro.2000.0584. PMID:11080488.
   PubMed Web of Science ®Google Scholar
• Zhou F, Leggatt GR, Frazer IH. Human papillomavirus 16 E7 protein inhibits interferon-gamma-mediated enhancement of keratinocyte antigen processing and T-cell lysis. FEBS J. 2011;278:955–63. doi:10.1111/j.1742-4658.2011.08011.x. PMID:21232015.
   PubMed Web of Science ®Google Scholar
• Cao Y, Zhao J, Lei Z, Shen S, Liu C, Li D, Liu J, Shen GX, Zhang GM, Feng ZH, et al. Local accumulation of FOXP3+ regulatory T cells: evidence for an immune evasion mechanism in patients with large condylomata acuminata. J Immunol. 2008;180:7681–6. doi:10.4049/jimmunol.180.11.7681. PMID:18490771.
   PubMed Web of Science ®Google Scholar
• Richards KH, Doble R, Wasson CW, Haider M, Blair GE, Wittmann M, Macdonald A. Human papillomavirus E7 oncoprotein increases production of the anti-inflammatory interleukin-18 binding protein in keratinocytes. J Virol. 2014;88:4173–9. doi:10.1128/JVI.02546-13. PMID:24478434
   PubMed Web of Science ®Google Scholar
• Xie Z, Zhang M, Xiong W, Wan HY, Zhao XC, Xie T, Lei H, Lin ZC, Luo DS, Liang XL, et al. Immunotolerant indoleamine-2,3-dioxygenase increases in condyloma acuminata. Br J Dermatol. 2017. doi:10.1111/bjd.15356.
   Web of Science ®Google Scholar
• Beutner KR, Spruance SL, Hougham AJ, Fox TL, Owens ML, Douglas JM, Jr. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol. 1998;38(2 Pt 1):230–9. doi:10.1016/S0190-9622(98)70243-9. PMID:9486679.
   PubMed Web of Science ®Google Scholar
• Beutner KR, Tyring SK, Trofatter KF, Jr., Douglas JM, Jr., Spruance S, Owens ML, Fox TL, Hougham AJ, Schmitt KA. Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother. 1998;42:789–94. PMID:9559784
   PubMed Web of Science ®Google Scholar
• Davis G, Wentworth J, Richard J. Self-administered topical imiquimod treatment of vulvar intraepithelial neoplasia. A report of four cases. J Reprod Med. 2000;45:619–23. PMID:10986679
   PubMed Web of Science ®Google Scholar
• Edwards L. Imiquimod in clinical practice. J Am Acad Dermatol. 2000;43:S12–17. doi:10.1067/mjd.2000.107806. PMID:10861102.
   PubMed Web of Science ®Google Scholar
• Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002;3:196–200. doi:10.1038/ni758. PMID:11812998.
   PubMed Web of Science ®Google Scholar
• Arany I, Tyring SK, Stanley MA, Tomai MA, Miller RL, Smith MH, McDermott DJ, Slade HB. Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%. Antiviral Res. 1999;43:55–63. doi:10.1016/S0166-3542(99)00033-9. PMID:10480263.
   PubMed Web of Science ®Google Scholar
• Soong RS, Song L, Trieu J, Knoff J, He L, Tsai YC, Huh W, Chang YN, Cheng WF, Roden RB, et al. Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNgamma. Clin Cancer Res. 2014;20:5456–67. doi:10.1158/1078-0432.CCR-14-0344. PMID:24893628.
   PubMed Web of Science ®Google Scholar
• Schon MP, Schon M. Imiquimod: mode of action. Br J Dermatol. 2007;157 Suppl 2:8–13. doi:10.1111/j.1365-2133.2007.08265.x. PMID:18067624.
   PubMed Web of Science ®Google Scholar
• Huang SW, Chang SH, Mu SW, Jiang HY, Wang ST, Kao JK, Huang JL, Wu CY, Chen YJ, Shieh JJ. Imiquimod activates p53-dependent apoptosis in a human basal cell carcinoma cell line. J Dermatol Sci. 2016;81:182–91. doi:10.1016/j.jdermsci.2015.12.011. PMID:26775629.
   PubMed Web of Science ®Google Scholar
• Sohn KC, Li ZJ, Choi DK, Zhang T, Lim JW, Chang IK, Hur GM, Im M, Lee Y, Seo YJ, et al. Imiquimod induces apoptosis of squamous cell carcinoma (SCC) cells via regulation of A20. PLoS One. 2014;9:e95337. doi:10.1371/journal.pone.0095337. PMID:24743316.
   PubMed Web of Science ®Google Scholar
• Sauder DN, Skinner RB, Fox TL, Owens ML. Topical imiquimod 5% cream as an effective treatment for external genital and perianal warts in different patient populations. Sex Transm Dis. 2003;30:124–8. doi:10.1097/00007435-200302000-00006. PMID:12567169.
   PubMed Web of Science ®Google Scholar
• Rosen T, Nelson A, Ault K. Imiquimod cream 2.5% and 3.75% applied once daily to treat external genital warts in men. Cutis. 2015;96:277–82. PMID:26682290.
   PubMed Web of Science ®Google Scholar
• Berman B, Wolf J. The role of imiquimod 3.75% cream in the treatment of external genital warts. Skin Therapy Lett. 2012;17:5–7. PMID:22491804.
   PubMedGoogle Scholar
• Edwards L, Ferenczy A, Eron L, Baker D, Owens ML, Fox TL, Hougham AJ, Schmitt KA. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV study group. human papillomavirus. Arch Dermatol. 1998;134:25–30. doi:10.1001/archderm.134.1.25. PMID:9449906.
   PubMed Web of Science ®Google Scholar
• Moore RA, Edwards JE, Hopwood J, Hicks D. Imiquimod for the treatment of genital warts: a quantitative systematic review. BMC Infect Dis. 2001;1:3. doi:10.1186/1471-2334-1-3. PMID:11401728.
   PubMed Web of Science ®Google Scholar
• Richards KH, Wasson CW, Watherston O, Doble R, Blair GE, Wittmann M, Macdonald A. The human papillomavirus (HPV) E7 protein antagonises an Imiquimod-induced inflammatory pathway in primary human keratinocytes. Sci Rep. 2015;5:12922. doi:10.1038/srep12922. PMID:26268216.
   PubMed Web of Science ®Google Scholar
• O'Garra A, Barrat FJ, Castro AG, Vicari A, Hawrylowicz C. Strategies for use of IL-10 or its antagonists in human disease. Immunol Rev. 2008;223:114–31. doi:10.1111/j.1600-065X.2008.00635.x. PMID:18613832.
   PubMed Web of Science ®Google Scholar
• Howard M, O'Garra A. Biological properties of interleukin 10. Immunol Today. 1992;13:198–200. doi:10.1016/0167-5699(92)90153-X. PMID:1385707.
   PubMedGoogle Scholar
• Shouval DS, Ouahed J, Biswas A, Goettel JA, Horwitz BH, Klein C, Muise AM, Snapper SB. Interleukin 10 receptor signaling: master regulator of intestinal mucosal homeostasis in mice and humans. Adv Immunol. 2014;122:177–210. doi:10.1016/B978-0-12-800267-4.00005-5. PMID:24507158.
   PubMed Web of Science ®Google Scholar
• Lu H, Wagner WM, Gad E, Yang Y, Duan H, Amon LM, Van Denend N, Larson ER, Chang A, Tufvesson H, et al. Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade. J Immunol. 2010;184:5360–7. doi:10.4049/jimmunol.0902997. PMID:20308630.
   PubMed Web of Science ®Google Scholar
• Alrefai H, Muhammad K, Rudolf R, Pham DA, Klein-Hessling S, Patra AK, Avots A, Bukur V, Sahin U, Tenzer S, et al. NFATc1 supports imiquimod-induced skin inflammation by suppressing IL-10 synthesis in B cells. Nat Commun. 2016;7:11724. doi:10.1038/ncomms11724. PMID:27222343.
   PubMed Web of Science ®Google Scholar
• Ni G, Chen S, Yang Y, Cummins SF, Zhan J, Li Z, Zhu B, Mounsey K, Walton S, Wei MQ, et al. Investigation the Possibility of Using Peptides with a Helical Repeating Pattern of Hydro-Phobic and Hydrophilic Residues to Inhibit IL-10. PLoS One. 2016;11:e0153939. doi:10.1371/journal.pone.0153939. PMID:27100390.
   PubMed Web of Science ®Google Scholar
• Ni G, Wang T, Walton S, Zhu B, Chen S, Wu X, Wang Y, Wei MQ, Liu X. Manipulating IL-10 signalling blockade for better immunotherapy. Cell Immunol. 2015;293:126–9. doi:10.1016/j.cellimm.2014.12.012. PMID:25596475.
   PubMed Web of Science ®Google Scholar
• Ni G, Wang Y, Cummins S, Walton S, Mounsey K, Liu X, Wei MQ, Wang T. Inhibitory mechanism of peptides with a repeating hydrophobic and hydrophilic residue pattern on interleukin-10. Hum Vaccin Immunother. 2017;13:518–527. doi:10.1080/21645515.2016.1238537.
   PubMed Web of Science ®Google Scholar
• Ni G, Liao Z, Chen S, Wang T, Yuan J, Pan X, Mounsey K, Cavezza S, Liu X, Wei MQ. Blocking IL-10 signalling at the time of immunization does not increase unwanted side effects in mice. BMC Immunol. 2017;18:40. doi:10.1186/s12865-017-0224-x. PMID:28810829.
   PubMed Web of Science ®Google Scholar
• Steinborner ST, Currie GJ, Bowie JH, Wallace JC, Tyler MJ. New antibiotic caerin 1 peptides from the skin secretion of the Australian tree frog Litoria chloris. Comparison of the activities of the caerin 1 peptides from the genus Litoria. J Pept Res. 1998;51:121–6. doi:10.1111/j.1399-3011.1998.tb00629.x. PMID:9516047.
   PubMedGoogle Scholar
• Bowie JH, Separovic F, Tyler MJ. Host-defense peptides of Australian anurans. Part 2. Structure, activity, mechanism of action, and evolutionary significance. Peptides. 2012;37:174–88. doi:10.1016/j.peptides.2012.06.017. PMID:22771617.
   PubMed Web of Science ®Google Scholar
• Pukala TL, Bowie JH, Maselli VM, Musgrave IF, Tyler MJ. Host-defence peptides from the glandular secretions of amphibians: structure and activity. Nat Prod Rep. 2006;23:368–93. doi:10.1039/b512118n. PMID:16741585.
   PubMed Web of Science ®Google Scholar
• Wong H, Bowie JH, Carver JA. The solution structure and activity of caerin 1.1, an antimicrobial peptide from the Australian green tree frog, Litoria splendida. Eur J Biochem. 1997;247:545–57. doi:10.1111/j.1432-1033.1997.00545.x. PMID:9266696.
   PubMedGoogle Scholar
• Apponyi MA, Pukala TL, Brinkworth CS, Maselli VM, Bowie JH, Tyler MJ, Booker GW, Wallace JC, Carver JA, Separovic F, et al. Host-defence peptides of Australian anurans: structure, mechanism of action and evolutionary significance. Peptides. 2004;25:1035–54. doi:10.1016/j.peptides.2004.03.006. PMID:15203252.
   PubMed Web of Science ®Google Scholar
• Berzofsky JA. A push-pull vaccine strategy using Toll-like receptor ligands, IL-15, and blockade of negative regulation to improve the quality and quantity of T cell immune responses. Vaccine. 2012;30:4323–7. doi:10.1016/j.vaccine.2011.11.034. PMID:22115635.
   PubMed Web of Science ®Google Scholar
• Gupta K, Cooper C. A review of the role of CpG oligodeoxynucleotides as toll-like receptor 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases. Drugs R D. 2008;9:137–45. doi:10.2165/00126839-200809030-00001. PMID:18457466.
   PubMed Web of Science ®Google Scholar
• Mauldin IS, Wages NA, Stowman AM, Wang E, Olson WC, Deacon DH, Smith KT, Galeassi N, Teague JE, Smolkin ME, et al. Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases. Cancer Immunol Immunother. 2016;65:1201–12. doi:10.1007/s00262-016-1880-z. PMID:27522582.
   PubMed Web of Science ®Google Scholar
• Cox JT, Petry KU, Rylander E, Roy M. Using imiquimod for genital warts in female patients. J Womens Health (Larchmt). 2004;13:265–71. doi:10.1089/154099904323016428. PMID:15130255.
   PubMed Web of Science ®Google Scholar
• Chuang CM, Monie A, Hung CF, Wu TC. Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination. J Biomed Sci. 2010;17:32. doi:10.1186/1423-0127-17-32. PMID:20426849.
   PubMed Web of Science ®Google Scholar